Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Refractory Mixed Phenotype Acute Leukemia Clear all
Recruiting Phase 1Phase 2 Interventional

A Study of Revumenib and Mezigdomide in People With Leukemia

NCT07356154
View directory record Official record
Conditions
Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Revumenib, Mezigdomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Phase 1 Interventional

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT03326921
View directory record Official record
Conditions
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Myelodysplastic Syndrome, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Biphenotypic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Active, not recruiting Phase 1 Interventional

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT02159495
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Adult Acute Lymphoblastic Leukemia, Interleukin-3 Receptor Subunit Alpha Positive, Minimal Residual Disease, Refractory Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Fludarabine Phosphate
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

NCT04827745
View directory record Official record
Conditions
Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD)
Interventions
BLINCYTO (Blinatumomab)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 2, 2026, 4:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

NCT04067336
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Interventions
Ziftomenib, Midazolam, Itraconazole
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT04975919
View directory record Official record
Conditions
Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

NCT03683433
View directory record Official record
Conditions
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Enasidenib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Terminated Phase 1 Interventional Results available

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

NCT01887587
View directory record Official record
Conditions
Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
MLN9708, Vincristine, Doxorubicin, Dexamethasone
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 2, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

NCT01858740
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Peripheral Blood Stem Cell Transplantation, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT03128034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Biospecimen Collection, Single Photon Emission Computed Tomography
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

NCT05146739
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine, Leucovorin, Triple Intrathecal Chemotherapy, Uproleselan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

NCT02220985
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Donor, Lymphoblastic Lymphoma, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03670966
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Mycophenolate Mofetil, Recombinant Granulocyte Colony-Stimulating Factor, Fludarabine Phosphate, Tacrolimus, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Biological · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

NCT00719888
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma
Interventions
Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation, Fludarabine, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Thiotepa
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Phase 1 Interventional

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT05476770
View directory record Official record
Conditions
Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Interventions
Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
29
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 2, 2026, 4:29 AM EDT
Active, not recruiting Phase 1 Interventional

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

NCT06325748
View directory record Official record
Conditions
AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
Interventions
SENTI-202
Biological
Lead sponsor
Senti Biosciences
Industry
Eligibility
18 Years to 74 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Completed Phase 1 Interventional

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

NCT03194932
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Venetoclax, Cytarabine, Idarubicin, Intrathecal Triple Therapy, Azacitidine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Palo Alto, California • Chapel Hill, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04047641
View directory record Official record
Conditions
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions
Cladribine, Cytarabine, Idarubicin, Quizartinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

NCT02044796
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 2, 2026, 4:29 AM EDT
Terminated Phase 2 Interventional

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

NCT03404193
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia
Interventions
Decitabine, Laboratory Biomarker Analysis, Venetoclax
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

NCT04874194
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Omacetaxine Mepesuccinate, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Not applicable Interventional

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

NCT05794880
View directory record Official record
Conditions
Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia, Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia With Crisis of Blast Cells, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Burkitt Leukemia, Lymphoma After Relapse, Other Malignant Hematologic Diseases in Remission
Interventions
Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
0 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

NCT06928662
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Acute Undifferentiated Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine, Echocardiography Test, Filgrastim, Fludarabine, Hematopoietic Cell Transplantation, Idarubicin, Multigated Acquisition Scan, Pheresis, Total-Body Irradiation, Biospecimen Collection
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 2, 2026, 4:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT06533579
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101
Genetic
Lead sponsor
Vironexis Biotherapeutics Inc.
Industry
Eligibility
13 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 2, 2026, 4:29 AM EDT